Загрузка...
Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress
The ability of the Cav1 channel inhibitor isradipine to slow the loss of substantia nigra pars compacta (SNc) dopaminergic (DA) neurons and the progression of Parkinson’s disease (PD) is being tested in a phase 3 human clinical trial. But it is unclear whether and how chronic isradipine treatment wi...
Сохранить в:
| Опубликовано в: : | J Clin Invest |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Clinical Investigation
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5983329/ https://ncbi.nlm.nih.gov/pubmed/29708514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI95898 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|